TransCode Collaborated with MD Anderson to Advance RNA Therapies for the Treatment of Cancer
Shots:
- The companies collaborated to advance TransCode’s pipeline of RNA-targeted oncology therapies and diagnostic products for the treatment of cancer
- In order to broaden the use of TransCode's discovery engine and to further validate the therapeutic & diagnostic candidates, TransCode & MD Anderson scientists will work together on preclinical research
- The collaboration could influence numerous clinical programs in TransCode's pipeline, beginning with TTX-MC138 for metastatic cancers. The P-0 trial is expected to be initiated for TTX-MC138 to deliver therapeutic candidate to metastatic lesions in patients with advanced solid tumors
Ref: TransCode Therapeutics | Image: TransCode Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
